Stay updated on Entrectinib in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Entrectinib in Solid Tumors Clinical Trial page.

Latest updates to the Entrectinib in Solid Tumors Clinical Trial page
- CheckyesterdayChange DetectedThe page has removed specific references to three clinical trial analyses involving entrectinib and crizotinib, while retaining similar content from other studies on the same drug's effectiveness in treating ROS1+ NSCLC and NTRK fusion-positive solid tumors.SummaryDifference2%
- Check8 days agoChange DetectedDifference1%
- Check16 days agoChange DetectedDifference1%
- Check23 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference1%
- Check30 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed study descriptions and inclusion/exclusion criteria for a clinical trial involving entrectinib, while adding a list of cancer types and a new revision number.SummaryDifference15%
- Check37 days agoChange DetectedThe date '2025-03-17' has been added, while '2025-03-25' has been removed from the page.SummaryDifference1%
Stay in the know with updates to Entrectinib in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Entrectinib in Solid Tumors Clinical Trial page.